Loss of leptin actions in obesity: Two concepts with cardiovascular implications

Clinical and Experimental Hypertension

Volumn 26, Issue 7-8, 2004, Pages 629-636

  Mark, Allyn L ^a,b,d   Correia, Marcelo L G ^a,b   Rahmouni, Kamal ^a,b   Haynes, William G ^a,b,c  

^a UNIVERSITY OF IOWA   (United States)

^b UNIVERSITY OF IOWA   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF IOWA   (United States)

Author keywords

Lipotoxicity; Selective leptin resistance; Sympathetic nervous system

Indexed keywords

LEPTIN;

ADRENERGIC SYSTEM; ANIMAL MODEL; CARDIOVASCULAR RISK; CONFERENCE PAPER; DISEASE ASSOCIATION; HEART DISEASE; HUMAN; HYPERTENSION; INSULIN DEFICIENCY; INSULIN RESISTANCE; LIPID STORAGE; NONHUMAN; OBESITY; PANCREAS ISLET CELL; SKELETAL MUSCLE;

ANIMALS; HEART DISEASES; HUMANS; HYPERTENSION; LEPTIN; LIPID METABOLISM; OBESITY; RISK FACTORS;

EID: 12344327340     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.1081/CEH-200031948     Document Type: Conference Paper

References (24)

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature 1994; 373:425-432.
2. Halaas JL, Boozer C, Blair-West J, Fidahausein N, Denton DA, Friedman JM. Physiological response to long-term peripheral and central leptin infusion in lean and obese mice. Proc Natl Acad Sci U S A 1997; 94:8878-8883.
3. Lembo G, Vecchione C, Fratta L, Marino G, Trimarco V, d'Amati G, Trimarco B. Leptin induces director vasodilation through distinct endothelial mechanisms. Diabetes 2000; 49:293-297.
4. Tartaglia LA, Dembski M, Weng X, Deng N, Culpepper J, Devos R, Richards GJ, Campfield LA, Clark FT, Deeds J. Identification and expression of cloning of a leptin receptor, OB-R. Cell 1995; 83:1263-1271.
5. Montague CT, Farooqi IS, Whitehead JP, Soos MA, Rau H, Wareham NJ, Sewter CP, Digby JE, Mohammed SN, Hurst JA, Cheetham CH, Barley AR, Barnett AH, Prins JB, O'Rahilly S. Congenital leptin deficiency in associated with severe early onset obesity in humans. Nature 1997; 387:903-907.
6. Clement K, Vaisse C, Lahlou N, Cabrol S, Pellous V, Cassuto D, Gourmelen M, Dina C, Chambaz J, Lacorte JM, Basdevant A, Bougneres P, Lebouc Y, Froguel P, Guy-Grand B. A mutation in the human leptin receptor gene causes obesity and pituitary dysfunction. Nature 1998; 392:388-401.
7. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, Ohannesian JP, Marco CC, McKee LJ, Bauer TL. Serum immunoreactive leptin concentrations in normal-weight and obese humans. N Eng J Med 1996; 334:292-295.
8. Steinberg GR, Parolin ML, Heigenhauser GJF, Dyck DJ. Leptin increases FA oxidation in lean but not obese human skeletal muscle: evidence of peripheral leptin resistance. Am J Physiol Endocrinol Metab 2002; 283:E187-E192.
9. Wallace AM, McMahon AD, Packard CJ, Kelly A, Shepherd J, Gaw A, Sattar N. Plasma leptin and the risk of cardiovascular disease in the west of Scotland coronary prevention study (WOSCOPS). Circulation 2001; 104:3052-3056.
10. Barba G, Russo O, Siani A, Iacone R, Farinaro E, Russo P, Venezia A, Strazzullo P. Independent relationship between plasma leptin levels and high blood pressure: the Olivetti heart study. J Hypertens 2001; 19(2):S96 (Abstract).
11. Correia MLG, Haynes WG, Rahmouni K, Morgan DA, Sivitz WI, Mark AL. The concept of selective leptin resistance: evidence from agouti yellow obese mice. Diabetes 2002; 51:439-442.
12. Mark AL, Correia MLG, Rahmouni K, Haynes WG. Selective leptin resistance: a new concept in leptin physiology with cardiovascular implications. J Hypertens 2002; 20:1245-1250.
13. Haynes WG, Morgan DA, Walsh SA, Mark AL, Sivitz WL. Receptor mediated regional sympathetic nerve activation by leptin. J Clin Invest 1997; 100:270-278.
14. Shek EW, Brands MW, Hall JE. Chronic leptin infusion increases arterial pressure. Hypertension 1998; 31:409-411.
15. Aizawa-Abe M, Ogawa Y, Masuzaki H, Ebinhara K, Satoh N, Iwai H, Matsuoka N, Hayashi T, Hosoda K, Inoue G, Yoshimasa Y, Nakao K. Pathophysiological role of leptin in obesity-related hypertension. J Clin Invest 2000; 105:1243-1252.
16. Mark AL, Shaffer RA, Correia MLG, Morgan DA, Sigmund CD, Haynes WG. Contrasting blood pressure effects of obesity in leptin-deficient ob/ob mice and agouti yellow obese mice. J Hypertens 1999; 17:1949-1953.
17. Morgan DA, Rahmouni K, Mark AL, Haynes WG. Selective leptin resistance during high fat diet in mice: preservation of sympathetic activation despite attenuation of metabolic responses. Hypertension 2001; 38:478.
18. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401:73-76.
19. Unger RH. Leptin physiology: a second look. Regulatory Pept 2000; 92:87-95.
20. Unger RH, Orci L. Liptoxic diseases of nonadipose tissues in obesity. Int J Obes 2000; 24(suppl 4):S28-S32.
21. Unger RH, Orci L. Diseases of liporegulation: new perspective on obesity and related disorders. Faseb J 2001; 15:312-321.
22. Zhou Y, Grayburn P, Karim A, Shimabukuro M, Higa M, Baetens D, Orci L, Unger RH. Lipotoxic heart disease in obese rats: implications for human obesity. PNAS 2000; 97:1784-1789.
23. Oral EA, Simha V, Ruiz E, Andewelt A, Premkumar A, Snell P, Wagner AJ, DePaoli AM, Reitman ML, Taylor SI, Gorden P, Garg A. Leptin-replacement therapy for lipodystrophy. N Engl J Med 2002; 346(8):570-578.
24. Simha V, Szczepaniak LS, Wagner AJ, DePaoli AM, Garg A. Effect of leptin replacement on intrahepatic and intramyocellular lipid content in patients with generalized lipodystrophy. Diabetes Care 2003; 26:30-35.